Table 4 Secondary endpoints: clinical response and pathological complete response rates in Cohort C (HR+ HER2low).

From: Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer

Eligible patients

23

Overall clinical response

18 (78.3%, 95% CI 56.3–92.5)

 Complete response

3 (13.0%, 95% CI 2.8–33.6)

 Partial response

15 (65.2%, 95% CI 42.7–83.6)

Stable disease

4 (17.4%, 95% CI 5.0–38.8)

Progressive disease

1 (4.3%, 95% CI 0.1–21.9)

Pathological complete response (absence of invasive cells in breast and axilla)

0

  1. CI confidence interval.
Back to article page